Christopher Mason's most recent trade in Krystal Biotech Inc was a trade of 5,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 30, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Krystal Biotech Inc | Christopher Mason | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2025 | 5,000 | 5,000 | - | - | Stock Option (Right to Buy) | |
| Krystal Biotech Inc | Christopher Mason | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2024 | 5,000 | 5,000 | - | - | Stock Option (Right to Buy) | |
| Krystal Biotech Inc | Christopher Mason | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2023 | 6,800 | 6,800 | - | - | Stock Option (Right to Buy) | |
| Krystal Biotech Inc | Christopher Mason | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2022 | 6,800 | 6,800 | - | - | Stock Option (Right to Buy) | |
| Krystal Biotech Inc | Christopher Mason | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2021 | 6,800 | 6,800 | - | - | Stock Option (Right to Buy) | |
| Tectonic Therapeutic Inc | Christopher Mason | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2021 | 125,000 | 125,000 | - | - | Stock Option (Right to Buy) |